XORTX Therapeutics stock gained 1.76 percent as FDA plan advances

Published on 10/07/2026 at 07:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

XORTX Therapeutics stock was last at USD 1.73 on October 6, 2026, while its FDA plan targets a USD 700 million annual U.S. market. Q2 2026 is the latest listed result.

XRTX, CA98420Q4051, Illustration mit AI erstellt.

XORTX Therapeutics stock (ISIN CA98420Q4051) was last at USD 1.73 on Nasdaq at 4:00 p.m. ET on October 6, 2026, up 1.76 percent from the previous close. The move followed the company's plan to submit an FDA application for its XRx-026 gout program in the fourth quarter of 2026.

FDA plan sets the central milestone

According to XORTX Therapeutics on September 18, 2026, the planned Investigational New Drug submission would advance XRx-026 toward clinical development for gout. The company says the program uses XORLO, its proprietary formulation of oxypurinol, and is built around the planned two-part XRX-OXY-102 trial.

The same release places the commercial opportunity at USD 700 million per year in the United States, based on prior peak net sales for febuxostat. That figure is a company estimate, while the regulatory timetable remains dependent on funding, trial execution and FDA agreement with the proposed development path.

Market value stays near the yearly floor

At USD 1.73, XORTX stock stood 8.8 percent above its 52-week low of USD 1.59 and 75.5 percent below its 52-week high of USD 7.05 on October 6, 2026. The session volume was 40,937 shares, giving the 1.76 percent daily gain a limited-volume profile.

The price action matters because the company is still moving through a development-stage pipeline rather than reporting commercial product sales. The investor-relations page identifies Q2 2026 as the latest financial-results period and fiscal year 2025 as the latest annual filing, while describing four programs across gout, kidney disease and acute organ injury, according to XORTX Therapeutics.

Clinical execution remains decisive

The XRx-026 plan requires meetings with the FDA, a pharmacokinetic and efficacy study, and production of commercial-scale XORLO supplies. The company also says a successful XRX-OXY-102 trial would support a pre-NDA meeting and later marketing-application preparation, according to XORTX Therapeutics.

XORTX Therapeutics stock was last at USD 1.73

XORTX Therapeutics stock was last at USD 1.73 on Nasdaq on October 6, 2026, with the 52-week range at USD 1.59 to USD 7.05. The next valuation step depends on progress toward the planned fourth-quarter FDA submission rather than on current product revenue.